CPT code 0067U designates the BBDRisk Dx™ Proprietary Laboratory Analyses (PLA) test from Silbiotech, Inc., a biomarker assay that estimates five-year breast cancer risk for women with specific precancerous breast lesions. As a PLA code, 0067U applies uniquely to a single manufacturer’s test and signals to payers and providers that the service is a proprietary diagnostic assay with a defined clinical purpose. Nationally, PLA codes like 0067U matter because they streamline identification of novel and company-specific laboratory diagnostics and affect coverage, coding clarity, and claims processing.

Key payers referenced in analyses include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise briefing on the clinical context of the assay, how 0067U is categorized within CPT as a PLA code, and the typical service setting for administration. The publication provides benchmarks and policy-relevant notes useful for billing and payer engagement, including common modifier usage and payer coverage coverage patterns where available. It also summarizes documentation and coding considerations relevant to laboratory and pathology service lines. Data not available in the input is clearly indicated where applicable.